Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

Background Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing matura...

Descripció completa

Dades bibliogràfiques
Autors principals: Bart Neyns, Angela Vasaturo, Julia Katharina Schwarze, Gil Awada, Ramses Forsyth, Jens Tijtgat, Louise Cras, Christopher Bagnall, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet
Format: Article
Idioma:English
Publicat: BMJ Publishing Group 2022-09-01
Col·lecció:Journal for ImmunoTherapy of Cancer
Accés en línia:https://jitc.bmj.com/content/10/9/e005141.full

Internet

https://jitc.bmj.com/content/10/9/e005141.full

Ítems similars